Drug Approval | October 02, 2024
Zydus receives EIR for the transdermal manufacturing facility
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
These accolades highlight our unwavering commitment to maintaining the highest safety standards
This project is supported by the Irish Government through IDA Ireland
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Subscribe To Our Newsletter & Stay Updated
